Transgene S.A.
$0.85▼ 15.00%($-0.15)
TickerSpark Score
58/100
▌ Mixed
60
Valuation
40
Profitability
50
Growth
80
Health
60
Momentum
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TRGNF research report →
52-Week Range16% of range
Low
$0.70
Current
$0.85
High
$1.62
Company Overviewwww.transgene.fr
About the company
Transgene S. A. is a biotechnology company dedicated to the creation and advancement of therapeutic vaccines and oncolytic viruses.
- CEO
- Alessandro Riva
- IPO
- 2021
- Employees
- 144
- HQ
- Illkirch-Graffenstaden, FR
Price Chart
+21.43% · this period
Valuation
- Market Cap
- $122.57M
- P/E
- -2.90
- P/S
- 794.68
- P/B
- 0.99
- EV/EBITDA
- -2.62
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 357.66%
- Op Margin
- -29978.10%
- Net Margin
- -27389.78%
- ROE
- -63.53%
- ROIC
- -27.43%
Growth & Income
- Revenue
- $136.95K · -97.84%
- Net Income
- $-37,509,945 · -10.42%
- EPS
- $-0.26 · 23.53%
- Op Income
- $-41,054,617
- FCF YoY
- -41.10%
Performance & Tape
- 52W High
- $1.62
- 52W Low
- $0.70
- 50D MA
- $1.00
- 200D MA
- $0.79
- Beta
- 0.69
- Avg Volume
- 47
Get TickerSpark's AI analysis on TRGNF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Coverage · TRGNF
Our TRGNF coverage
Recent articles, reports, and earnings notes.
On-Demand Research
No research on TRGNF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TRGNF report →Internal Compare
Similar companies
Peers in the same neighborhood.